Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.75 |
| ▸ | KIT | P10721 | 6/20 | 0.75 |
| ▸ | FLT3 | P36888 | 4/20 | 0.75 |
| ▸ | AURKB | Q96GD4 | 13/20 | 0.74 |
| ▸ | AURKA | O14965 | 7/20 | 0.74 |
| ▸ | CSF1R | P07333 | 1/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.57 |
| ▸ | FLT1 | P17948 | 1/20 | 0.57 |
| ▸ | TEK | Q02763 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545808 | 0.87 | AURKB (0.72) | KDRKITFLT3AURKBAURKA | |
| SCHEMBL545738 | 0.86 | AURKB (0.83) | KDRKITFLT3AURKBAURKA | |
| SCHEMBL546030 | 0.86 | AURKB (0.69) | KDRKITFLT3AURKBAURKA | |
| SCHEMBL545527 | 0.86 | AURKB (1.00) | KDRKITFLT3AURKBAURKA | |
| SCHEMBL31531260 | 0.86 | KIT (1.00) | KDRKITFLT3CSF1RPDGFRB | |
| SCHEMBL421890 | 0.86 | KIT (1.00) | KDRKITFLT3CSF1RPDGFRB | |
| SCHEMBL546332 | 0.85 | AURKB (1.00) | KDRKITFLT3AURKBAURKA | |
| SCHEMBL545935 | 0.84 | AURKB (0.83) | KDRKITFLT3AURKBAURKA | |
| SCHEMBL546327 | 0.84 | AURKB (0.80) | KDRKITFLT3AURKBAURKA | |
| SCHEMBL546632 | 0.84 | AURKB (1.00) | KDRKITFLT3AURKBAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170834-B1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | ABBVIE INC (US) | 2014-01-08 | — | — | EP | claimed |
| US-8110572-B2 | Inhibitors of protein kinases | ABBOTT LABORATORIES (US) | 2012-02-07 | — | — | US | claimed |
| EP-2170834-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2010-04-07 | — | — | EP | claimed |
| US-20090054430-A1 | Inhibitors of Protein Kinases | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | claimed |
| WO-2009012312-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | claimed |
| EP-2170834-B1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | ABBVIE INC (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8110572-B2 | Inhibitors of protein kinases | ABBOTT LABORATORIES (US) | 2012-02-07 | — | — | US | disclosed |
| EP-2170834-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | Abbott Laboratories (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090054430-A1 | Inhibitors of Protein Kinases | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009012312-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054430-A1 | Inhibitors of Protein Kinases | AURKC, AURKB, PLK1 | KDR 2634/4885KIT 1253/4885FLT3 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.